Related Experiment Videos
T cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer
J C Zhao-Emonet1, G Marodon, C Pioche-Durieu
1Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires UPMC-CNRS ESA 7087-CERVI-H pital de la Pitié, Paris, France.
The Journal of Gene Medicine
|February 24, 2001
Summary
Researchers developed an efficient T cell-specific retroviral vector (RV) for gene therapy. This novel hybrid vector design achieves high titers and maintains T cell specificity, overcoming limitations of previous tissue-specific vectors.
Area of Science:
- Molecular Biology
- Gene Therapy
- Immunology
Background:
- Gene therapy holds promise for immunological disorders, but requires T cell-specific retroviral vectors (RVs).
- Existing tissue-specific vectors often suffer from low titers and loss of specificity.
- Developing a T cell-specific RV is crucial for advancing gene therapy applications.
Purpose of the Study:
- To engineer a T cell-specific retroviral vector (RV) with improved efficiency and specificity.
- To overcome the limitations of low titers and poor specificity in current tissue-specific vectors.
Main Methods:
- Constructed Moloney murine leukemia virus (Mo-MLV)-based RVs expressing enhanced green fluorescent protein (EGFP).
- Utilized a CD4 gene-derived mini-promoter/enhancer cassette (CD4pmE) in various vector configurations (SIN and hybrid).
- Assessed EGFP expression in cell lines and peripheral blood lymphocytes via fluorescence microscopy and flow cytometry.
Main Results:
- Self-inactivating (SIN) vectors with CD4pmE in sense orientation yielded high titers but poor specificity.
- Anti-sense orientation in SIN vectors resulted in low titers but high specificity.
- Hybrid vectors demonstrated both high titers and robust T cell specificity.
Conclusions:
- Successfully developed an efficient T cell-specific retroviral vector (RV).
- The hybrid vector design is a promising strategy for targeted gene delivery in T cells.
- This advancement facilitates the potential for improved gene therapy of immunological disorders.